Aashish Desai, MD
Interventional Cardiology · Canton, GANPI 1114000767
Payments from drug & device makers
Across 225 payments — averaging $40.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$1K
- Shockwave Medical, Inc$1K
- Penumbra, Inc.$779
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$774
- Novartis$582
- Medtronic$465
- plus $4K from 32 others
Across 1 payment — averaging $11.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Chiesi USA, Inc.$12
What the payments were for
- Travel & lodging$2,33926%
- Food & beverage$6,77974%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 12 | $1,477 |
| Shockwave Medical, Inc | 12 | $1,403 |
| Penumbra, Inc. | 4 | $779 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 17 | $774 |
| Novartis | 31 | $582 |
| Medtronic(2 entities) | 5 | $465 |
| Johnson & Johnson | 24 | $407 |
| Boston Scientific | 11 | $352 |
| Amgen | 19 | $335 |
| Abiomed | 5 | $314 |
| E.r. Squibb & Sons, L.L.C. | 13 | $297 |
| Philips North America LLC | 4 | $271 |
| Pfizer | 12 | $207 |
| Merck | 9 | $160 |
| Atricure, Inc. | 1 | $142 |
| Janssen Scientific Affairs, LLC | 1 | $133 |
| Boehringer Ingelheim | 6 | $127 |
| AstraZeneca | 6 | $112 |
| Heartflow, Inc. | 1 | $107 |
| Genentech, Inc. | 1 | $101 |
| Edwards Lifesciences | 4 | $80 |
| Amarin Pharma, Inc. | 4 | $75 |
| Esperion Therapeutics, Inc. | 4 | $64 |
| Angiodynamics, Inc. | 1 | $43 |
| Kowa Pharmaceuticals America, Inc. | 3 | $39 |
| Sanofi-aventis U.S. LLC | 2 | $35 |
| Chiesi USA, Inc. | 2 | $33 |
| Convatec Inc. | 1 | $25 |
| Alnylam Pharmaceuticals Inc. | 1 | $24 |
| Novo Nordisk | 1 | $21 |
| Phadia US Inc. | 1 | $20 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $19 |
| Amphastar Pharmaceuticals, Inc. | 1 | $19 |
| Actelion Pharmaceuticals US, Inc. | 1 | $18 |
| Siemens Medical Solutions USA, Inc. | 1 | $16 |
| Nuwellis, Inc. | 1 | $16 |
| Amryt Pharma Holdings Ltd | 1 | $14 |
| Baxter Healthcare | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$992
- Xience V coronary stent system$841
- Indigo System$702
- ONYX FRONTIER$162
- Mitra Clip system$154
- SYNERGY ABLATION SYSTEM$142
- Micra$141
- COROFLOW$138
- XARELTO$133
- PRESSUREWIRE$127
- WATCHMAN FLX$109
- Optis Coronary Imaging System$107
- FFRct$107
- Impella$106
- LifeVest$102
- Non-Covered Product$101
How this compares
$9,118 in reported general payments places this provider in the 50th percentile of 218 interventional cardiology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 620 | $675,872 |
| EntrestoSacubitril/Valsartan | 125 | $136,418 |
| XareltoRivaroxaban | 108 | $135,047 |
| CamzyosMavacamten | 13 | $100,490 |
| Repatha SureclickEvolocumab | 66 | $88,677 |
| FarxigaDapagliflozin Propanediol | 56 | $62,066 |
| JardianceEmpagliflozin | 49 | $46,131 |
| Praluent PenAlirocumab | 24 | $16,719 |
| BrilintaTicagrelor | 12 | $8,058 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 15 | $6,924 |
| Ranolazine ErRanolazine | 50 | $6,062 |
| Prasugrel Hcl | 34 | $4,911 |
| Atorvastatin Calcium | 461 | $4,629 |
| Metoprolol Succinate | 276 | $4,541 |
| Rosuvastatin Calcium | 393 | $4,004 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $207 | $675,872620 claims |
| NovartisEntresto | $582 | $136,418125 claims |
| Johnson & JohnsonXarelto | $407 | $135,047108 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $297 | $100,49013 claims |
| AstraZenecaFarxiga, Brilinta | $112 | $70,12468 claims |
| Boehringer IngelheimJardiance | $127 | $46,13149 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 218 interventional cardiology providers in Georgia.
Other interventional cardiology in Canton
- David KandzariAtlanta$3.7M
- Pradeep YadavAtlanta$3.5M
- Vasilis BabaliarosAtlanta$2.7M
- Megan CoylewrightCalhoun$2.3M
- William NicholsonAtlanta$2M
- Chandanreddy DevireddyAtlanta$1.9M
- Adam GreenbaumAtlanta$1.8M
- Amar PatelMarietta$1.8M
- Vivek RajagopalAtlanta$1.3M
- Christopher MeduriAtlanta$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.